Activated Charcoal Arnica Montana Whole Collinsoni
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Activated Charcoal Arnica Montana Whole Collinsoni
- Multi-Ingredient Homeopathic Combination: Insufficient Data for Repurposing Evaluation
Multi-Ingredient Homeopathic Combination: Insufficient Data for Repurposing Evaluation
One-Sentence Summary
This submission contains a 14-ingredient homeopathic combination product (including Activated Charcoal, Arnica Montana, Horse Chestnut, Hamamelis virginiana, and Strychnos nux-vomica, among others) with no registered market authorization in Taiwan. The TxGNN model returned no predicted indications for this candidate — likely because the query string was treated as a single unresolvable entity rather than individual active ingredients. Without a DrugBank ID, original indication data, or any model output, a meaningful repurposing evaluation cannot be completed at this time.
Quick Overview
| Item | Content |
|---|---|
| Drug Queried | Multi-ingredient homeopathic combination (14 components) |
| DrugBank ID | Not available |
| Predicted New Indication | None — TxGNN returned no results |
| Evidence Level | L5 (model prediction only, but no output generated) |
| Taiwan Market Status | Not marketed |
| Number of Licenses | 0 |
| Recommended Decision | Hold |
Why No Prediction Was Generated
The Evidence Pack reveals a structural data problem rather than a drug repurposing finding.
The drug query string submitted to TxGNN was the full concatenated INN list of all 14 ingredients (e.g., "ACTIVATED CHARCOAL; ARNICA MONTANA WHOLE; COLLINSONIA CANADENSIS ROOT; ..."). TxGNN operates by matching a single drug node in its knowledge graph; a multi-ingredient string like this will not match any node, causing the prediction pipeline to return zero results.
Additionally, no DrugBank ID was resolved (drugbank_id: null), which blocks the MOA lookup, indication crosswalk, and DDI queries. Without a DrugBank anchor, the system has no mechanism to characterize the compound or retrieve evidence.
From a pharmacological standpoint, the ingredient profile — Horse Chestnut (Aesculus hippocastanum), Hamamelis virginiana, Collinsonia canadensis, and Paeonia officinalis — is characteristic of classical homeopathic formulas targeting anorectal or venous congestion conditions (e.g., hemorrhoids, varicose veins). However, this clinical inference cannot be validated without actual regulatory filings or peer-reviewed evidence tied to this specific combination.
Conclusion and Next Steps
Decision: Hold
Rationale: The pipeline failed to produce any repurposing candidate because the drug was submitted as a single multi-ingredient string rather than resolved individual components. There is no TxGNN output, no regulatory data, and no safety profile on which to base any clinical recommendation.
To proceed, the following is needed:
- Decompose the submission: Identify the lead active ingredient (e.g., Horse Chestnut / Aesculus hippocastanum, DrugBank DB01593) and resubmit each component individually through the TxGNN pipeline.
- Resolve DrugBank IDs: Map each of the 14 ingredients to their respective DrugBank entries to enable MOA retrieval and DDI analysis.
- Identify the intended product: Determine whether this combination corresponds to a known commercial product (e.g., a branded hemorrhoidal homeopathic remedy) to obtain the original indication and label warnings.
- Rerun the evidence pack: Once individual DrugBank IDs are available, regenerate clinical trial and literature evidence for each component separately.
- Consider pipeline-level fix: The TxGNN query logic should handle multi-ingredient products by splitting on
;and querying each component independently, then aggregating results.Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.